Aissaoui Dorra, Oulmoudne Naoual, Bahig Houda, Masucci Giuseppina Laura, Moumdjian Robert, Roberge David, Menard Cynthia, Létourneau-Guillon Laurent, Lambert Carole, Bahary Jean-Paul
Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Research Center, CRCHUM - Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Clin Transl Radiat Oncol. 2025 Jul 4;54:101010. doi: 10.1016/j.ctro.2025.101010. eCollection 2025 Sep.
Symptomatic posttreatment edema (SPTE) is a complication that may develop after radiotherapy for intracranial meningiomas. Our study aims at reviewing rates of SPTE in a large cohort of a single institution and identifying possible predictive factors.
We retrospectively analyzed data of 293 patients with 304 intracranial meningiomas irradiated at our institution between 2005 and 2018. We evaluated rates of SPTE and investigated numerous factors by univariate and multivariate analysis. Kaplan Meier analysis was used for estimation of actuarial local control and overall survival.
Median age was 60 years. Meningiomas were treated with fractionated stereotactic radiation therapy (70 %), single fraction stereotactic radiosurgery (24 %) or fractionated stereotactic radiosurgery (6 %). Median imaging follow-up was 60 months, actuarial 10 year local control rate for patients with grade 1 meningiomas who received radiotherapy as definitive treatment was 99 %. Local control at 5 years was 94 % for grade 1 meningioma, 57 % and 53 % for grade 2 and 3 respectively. Sixteen patients (5.5 %) developed SPTE, median time to onset was 3 months (range 1-26 months). the higher rates of SPTE observed were in midline (13 %) and convexity (9 %), compared to skull base tumors (2 %). On univariate analysis, age > 60 years (p > 0.03), pretreatment peritumoral edema (p = 0.014), medline location (p = 0.018), tumor size > 30 mm (p = 0.015) and grade 2 histology (p = 0.03) were predictive of SPTE. On multivariate analysis, only tumor location and size remained statistically significant.
Based on our results, patients at high risk of SPTE can be identified based on patient and tumor characteristics. The best treatment technique in high risk patients is yet to be defined.
症状性治疗后水肿(SPTE)是颅内脑膜瘤放疗后可能出现的一种并发症。我们的研究旨在回顾单一机构的一大群患者中SPTE的发生率,并确定可能的预测因素。
我们回顾性分析了2005年至2018年在我们机构接受放疗的293例患有304个颅内脑膜瘤患者的数据。我们评估了SPTE的发生率,并通过单因素和多因素分析研究了众多因素。采用Kaplan Meier分析来估计精算局部控制率和总生存率。
中位年龄为60岁。脑膜瘤采用分次立体定向放射治疗(70%)、单次立体定向放射外科治疗(24%)或分次立体定向放射外科治疗(6%)。中位影像学随访时间为60个月,接受放疗作为确定性治疗的1级脑膜瘤患者的精算10年局部控制率为99%。1级脑膜瘤5年局部控制率为94%,2级和3级分别为57%和53%。16例患者(5.5%)发生了SPTE,中位发病时间为3个月(范围1 - 26个月)。与颅底肿瘤(2%)相比,在中线(13%)和凸面(9%)观察到的SPTE发生率更高。单因素分析中,年龄>60岁(p>0.03)、治疗前瘤周水肿(p = 0.014)、中线位置(p = 0.018)、肿瘤大小>30mm(p = 0.015)和2级组织学(p = 0.03)是SPTE的预测因素。多因素分析中,只有肿瘤位置和大小仍具有统计学意义。
根据我们的结果,可以根据患者和肿瘤特征识别出SPTE高危患者。高危患者的最佳治疗技术尚待确定。